Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lanreotide + temozolomide
- Development stage
- Unknown
- Lead developer
- Ipsen
- Modality
- Peptides, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
Lanreotide + temozolomide is a combination therapy used primarily for the treatment of progressive neuroendocrine tumors, including gastroenteropancreatic and thoracic neuroendocrine tumors. Lanreotide is a synthetic somatostatin analog that acts mainly via somatostatin receptor subtypes 2 and 5, inhibiting hormone secretion and exerting antiproliferative effects on tumor cells. Temozolomide is an oral alkylating agent of the triazene class that methylates DNA at several sites, leading to cell cycle arrest and apoptosis in rapidly dividing tumor cells. The combination has shown efficacy in patients with advanced or metastatic well-differentiated neuroendocrine tumors who have progressed on other therapies, with a manageable safety profile[1][2][3][5].
- Brand names
- Somatuline Depot (lanreotide)
- Other names
- LANTMZ
02
Targets
SSTR5 (Somatostatin receptor 5)DNASSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on lanreotide + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lanreotide + temozolomide.